1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

03 Sep 2025
Admin
News Article

Glenmark to Launch Eribulin Mesylate Injection in September 2025

Glenmark Pharmaceuticals Ltd. has announced the launch of eribulin mesylate injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials, beginning distribution in September 2025.

Product Details

The product is bioequivalent and therapeutically equivalent to the reference listed drug Halaven® Injection (Eisai, Inc.).
Glenmark’s eribulin mesylate injection is approved only for the indications listed in Glenmark’s FDA-approved label.
Not all indications of the reference drug are marketed by Glenmark.
Packaged as 1 mg/2 mL (0.5 mg/mL) single-dose vials for institutional channel distribution.

Company Statement

Marc Kikuchi, President & Business Head, North America at Glenmark, said:

“We are pleased to announce the launch of eribulin mesylate injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials. As the first complex generic in our portfolio, this launch marks both our commitment to growing our portfolio of products within the institutional channel and reinforces our dedication to bring quality and affordable alternatives to market for patients in need.”

Market Context

The market includes brand Halaven® and available therapeutic equivalents.
Glenmark’s launch represents the company’s first complex generic product in the oncology space, strengthening its U.S. institutional channel presence.

About Glenmark Pharmaceuticals

Global presence: Operations in 80+ countries.
Infrastructure: 11 manufacturing facilities across 4 continents.
Focus areas: Respiratory, dermatology, and oncology.
Portfolio: Branded, generics, and OTC products.
Positioning: Research-led company committed to expanding affordable and quality treatment options worldwide.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!